Alaunos Therapeutics, Inc. Income Statement
TCRT|11 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 11 fiscal years. All figures from audited SEC 10-K filings.
Alaunos Therapeutics, Inc. reported $10,000 in revenue and $5M in net loss for FY2025. Revenue has declined at a 25.9% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0K | $5.0K | $2.9M | $398.0K | $0 | $146.0K | $15.9M | $15.9M | - | $667.0K | $667.0K |
| SG&A Expense | $4.5M | $12.2M | $13.1M | $27.6M | $27.7M | $19.9M | $14.8M | $14.4M | $251.0K | $251.0K | $7.6M |
| R&D Expense | $362.0K | $16.3M | $25.0M | $49.6M | $52.7M | $34.1M | $45.1M | $157.8M | $17.5M | $12.9M | $4.6M |
| Operating Income | -$4.8M | -$34.3M | -$35.1M | -$77.5M | -$80.4M | -$53.9M | -$53.5M | -$165.3M | -$71.4M | -$24.5M | -$12.1M |
| Interest Expense | - | $1.9M | $3.2M | $1.2M | $1.2M | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - | - |
| Net Income | -$4.7M | -$35.1M | -$37.7M | -$78.8M | -$80.0M | -$53.1M | -$54.3M | -$165.3M | -$5.7M | -$160.0K | -$160.0K |
| EPS (Basic) | -$2.92 | -$21.97 | -$2.61 | -$0.37 | - | $0.96 | -$0.53 | -$1.32 | - | - | - |
| EPS (Diluted) | -$2.92 | -$21.97 | -$2.61 | -$0.37 | -$0.38 | $0.96 | -$0.53 | -$1.32 | -$3.75 | -$3.75 | -$0.33 |
| Shares Outstanding | 1.6M | 1.6M | 16.0M | 216.1M | 214.6M | 181.8M | 161.1M | 142.7M | 83.2M | 69.2M | 48.5M |
| Operating Margin | -48120.0% | -685340.0% | -1201.4% | -19484.7% | - | -36921.9% | -336.4% | -1039.7% | - | -3680.1% | -1817.5% |
| Profit Margin | -46790.0% | -702800.0% | -1291.2% | -19786.7% | - | -36381.5% | -341.7% | -1039.6% | - | -24.0% | -24.0% |